Floatz logo

Tarlatamab

Respiratory Tract Neoplasms

Fundación GECPmonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

10 Active assets in the Respiratory Tract Neoplasms cohort.

Asset / SponsorPhaseRating
Carboplatin
Fundación GECP
Phase 3BB
Pralsetinib, trans-
Hoffmann-La Roche
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Nanfang Hospital, Southern Medical University
Phase 3BB
Pembrolizumab
Hoffmann-La Roche
Phase 3B
Docetaxel
University of Turin, Italy
Phase 3B

View all 25 →

Same molecule, other indications

Tarlatamab is also rated in:

small cell lung carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
medullary thyroid gland carcinomaDormant
B
Indicative ·
60 / 100
View asset →
neuroendocrine carcinomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →